These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31556762)

  • 21. Streamlining biosimilar development based on 20 years' experience.
    Nick C
    Expert Opin Biol Ther; 2024 Jul; 24(7):571-581. PubMed ID: 38315062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of bevacizumab biosimilar on wound healing complications in patients with colorectal cancer undergoing endoscopic mucosal resection: A systematic review and meta-analysis in anorectal medicine.
    Li Y; Mei Z; Shi L; Wan Y; Zhou X; Zeng T; Liu Y; Yang JY; Shi Z
    Int Wound J; 2024 Jan; 21(1):e14638. PubMed ID: 38272807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world use of IBI305, a bevacizumab biosimilar, in a tertiary caner-specialized hospital in China.
    Chen Z; Wang Y; Yang J; Zhou H; Li G
    J Clin Pharm Ther; 2022 Dec; 47(12):2274-2278. PubMed ID: 36418209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations.
    Kolberg HC; Demetriou GS; Hanes V
    Oncol Ther; 2021 Jun; 9(1):225-238. PubMed ID: 33428085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study.
    Bhattacharya S; Rathore AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123896. PubMed ID: 37776677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain.
    Calleja MA; Albanell J; Aranda E; García-Foncillas J; Feliu A; Rivera F; Oyagüez I; Salinas-Ortega L; Soto Alvarez J
    Eur J Hosp Pharm; 2023 Mar; 30(e1):e40-e47. PubMed ID: 34810173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Education strategy for the implementation of oncology biosimilars essential for operational and patient safety in Alberta, Canada.
    Garg M; Chatterjee A; Chambers CR
    J Oncol Pharm Pract; 2021 Jul; 27(5):1189-1194. PubMed ID: 33896268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
    Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
    Biologicals; 2021 Sep; 73():41-56. PubMed ID: 34593306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Financial toxicity and cancer treatments: Help from biosimilars - The explanatory case of bevacizumab.
    Giuliani J; Fiorica F; Albanese V; Bonetti A
    Eur J Cancer; 2021 Jan; 143():40-42. PubMed ID: 33278773
    [No Abstract]   [Full Text] [Related]  

  • 30. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
    Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
    Biologicals; 2022 Jun; 77():1-15. PubMed ID: 35667958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-clinical pharmacology and toxicology studies of bevacizumab biosimilar LY01008.
    Guangying D; Shuzhi M; Xiaoyin Z; Pengfei Y; Xin Y; Liang Y; Xin S; Baiping S; Changlin D; Hongbo W; Jingwei T
    Eur J Pharmacol; 2022 Dec; 936():175383. PubMed ID: 36347321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr).
    Ingram RL; Weiser SE
    Drugs R D; 2023 Mar; 23(1):55-64. PubMed ID: 36811761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Successful Continuation of Treatment in Advanced Colorectal Cancer by Switching to a Prior Biologic Agent after Emergence of Bevacizumab Allergy to a Biosimilar Drug-A Case Report].
    Ushigome M; Funahashi K; Yoshida K; Okubo K; Miura Y; Suzuki T; Kagami S; Nagashima Y; Koda T; Kaneko T; Kurihara A; Mitsuda A
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1603-1605. PubMed ID: 38303355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US.
    Jin R; Mahtani RL; Accortt N; Lawrence T; Sandschafer D; Loaiza-Bonilla A
    Ther Adv Med Oncol; 2021; 13():17588359211041961. PubMed ID: 35003333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns.
    Kumar A; Agarwal D; Kumar A
    Indian J Ophthalmol; 2021 Feb; 69(2):357-358. PubMed ID: 33463591
    [No Abstract]   [Full Text] [Related]  

  • 36. Commentary: Anti-vascular endothelial growth factor therapies in vitreo-retina practice: Biosimilars versus biologics.
    Anantharaman G
    Indian J Ophthalmol; 2021 Feb; 69(2):358-359. PubMed ID: 33463592
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparative stability study and aggregate analysis of Bevacizumab marketed formulations using advanced analytical techniques.
    Bana AA; Sajeev N; Halder S; Abbas Masi H; Patel S; Mehta P
    Heliyon; 2023 Sep; 9(9):e19478. PubMed ID: 37810070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approved biosimilar ranibizumab-a global update.
    Sharma A; Kondo M; Iwahashi C; Parachuri N; Kumar N; Bandello F; Loewenstein A; Kuppermann BD
    Eye (Lond); 2023 Feb; 37(2):200-202. PubMed ID: 36114290
    [No Abstract]   [Full Text] [Related]  

  • 39. Correction to: SB8: A Bevacizumab Biosimilar.
    Syed YY
    Target Oncol; 2021 Jan; 16(1):119. PubMed ID: 33306171
    [No Abstract]   [Full Text] [Related]  

  • 40. Correction to: MYL-1402O: A Bevacizumab Biosimilar.
    Lee A
    Target Oncol; 2022 May; 17(3):379. PubMed ID: 35437710
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.